DEF: Orgenesis Inc. Special Meeting: Share Increase and Loan Approval

Orgenesis Inc. is holding a special meeting on May 27, 2026, to vote on increasing authorized shares, approving a convertible loan agreement, and ratifying auditor appointment.

Summary

• Orgenesis Inc. is convening a special meeting of stockholders on May 27, 2026, to be held virtually via live audio webcast.
• The primary purposes of the meeting are to vote on increasing the number of authorized shares of common stock from 14,583,333 to 150,000,000.
• Stockholders will also vote on approving a convertible loan agreement dated September 10, 2025, with Alpha Prosperity Fund SPC, and the potential issuance of shares of common stock pursuant to this agreement.
• Additionally, the appointment of Kesselman & Kesselman C.P.A.s as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be ratified.
• The company's Board of Directors recommends voting FOR all three proposals.
• The record date for voting eligibility is April 22, 2026, with 9,799,538 shares of common stock outstanding on that date.
• The convertible loan agreement involves an initial $1,000,000 loan with a 10% annual interest rate and a 36-month maturity, with the lender having the option to convert into equity.
• A credit facility of up to $10,000,000 is also available, of which $10,000,000 has been drawn.
• Warrants to purchase an aggregate of 60,578,082 shares of common stock are to be issued in connection with the funds drawn down.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant dilution risk associated with the proposed share increase and convertible loan, despite the necessity for capital to continue operations.

Positives

• The company is seeking to increase its authorized share capital to provide flexibility for future corporate actions such as acquisitions, partnerships, equity incentive plans, and capital raising.
• The convertible loan agreement provides access to significant capital ($1,000,000 initial loan and up to $10,000,000 credit facility), which is crucial for continued operations.
• The virtual meeting format is intended to increase stockholder attendance and participation globally while reducing costs and environmental impact.
• The appointment of an independent auditor is a standard and necessary corporate governance practice.

Negatives

• The proposed increase in authorized shares and the potential issuance of shares pursuant to the convertible loan agreement and warrants could lead to significant dilution for existing stockholders.
• The potential issuance of up to 60,578,082 shares upon exercise of warrants could materially dilute existing ownership percentages.
• If the share issuance proposal is not approved, the company may be unable to repay the loan or receive proceeds from warrant exercises, potentially impacting its ability to continue operations.
• The convertible loan agreement allows the lender to convert the outstanding amount into up to 80% of the equity of the company or its subsidiary, Theracell Laboratories IKE, which represents a significant potential shift in control.

Risks

• The potential issuance of a large number of new shares could dilute the earnings per share, stockholders' equity, and voting rights of existing shareholders.
• Future sales of substantial amounts of common stock, or the perception of such sales, could adversely affect the market price of the company's common stock.
• The company's ability to raise additional capital in the future could be limited by the increased supply of shares.
• Failure to obtain stockholder approval for the share issuance could jeopardize the company's ability to repay the convertible loan and receive funds from warrant exercises, impacting its operational continuity.

Future Outlook

The company is seeking approval to increase authorized shares to provide flexibility for future corporate actions, including acquisitions, partnerships, equity incentive plans, and capital raising. The approval of the convertible loan agreement and potential share issuance is critical for continued operations and to avoid potential inability to repay the loan or receive proceeds from warrant exercises.

Management Comments

• Our Board of Directors recommends the approval of each of these proposals.
• We believe hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our Special Meeting.
• Our Board of Directors believes that the authorized number of shares of Common Stock should be increased as a matter of good corporate governance to provide sufficient shares for such corporate purposes as may reasonably be determined by the Board to be necessary and in the best interest of the Company and our stockholders.
• After extensive efforts to raise capital on more favorable terms, we believed that the Convertible Loan Agreement was the only viable financing alternative available to us at the time.

Industry Context

StockSavvy.ai notes that increasing authorized shares and securing financing through convertible instruments are common strategies for biotechnology and life sciences companies, particularly those in development stages, to fund ongoing research, clinical trials, and potential expansion. However, these actions often come with significant dilution risk for existing shareholders, a factor investors closely scrutinize.

Corporate Governance

Related Party Transactions

• The convertible loan agreement is between Orgenesis Inc. (and its subsidiary Theracell Laboratories IKE) and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P. The nature of the relationship between these entities and their beneficial owners is not detailed beyond the fund structure, but the significant equity stake and conversion options suggest a close financial relationship.

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership percentage, earnings per share, and voting rights. Also, the capital raise is critical for the company's continued operations, which is a positive for long-term value if successful.
• Creditors: The capital raise and potential equity conversion could impact the company's debt structure and future borrowing capacity.
• Management: The approval of these proposals is crucial for management's ability to execute future strategic plans and secure necessary funding.

Next Steps

• Stockholders to vote on the three proposals at the Special Meeting on May 27, 2026.
• If approved, the company will amend its Articles of Incorporation to increase authorized shares.
• If approved, the company will proceed with the potential issuance of shares under the convertible loan agreement and exercise of warrants.
• The company will publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the Special Meeting.

Key Dates

Recommendation

The company requires significant capital for operations, and the proposed financing through a convertible loan and share issuance is a necessary step. However, the substantial dilution risk associated with these proposals, including the potential for the lender to acquire up to 80% of the company's equity, warrants a cautious approach. Existing shareholders should monitor the execution of the company's strategy post-financing. For new investors, the dilution risk makes it prudent to wait for clearer signs of operational progress and value creation before committing capital.

Keywords

Orgenesis Inc., Special Meeting, Proxy Statement, Authorized Shares, Convertible Loan, Share Issuance, Stockholder Approval, Dilution, Independent Auditor, Theracell Laboratories, Alpha Prosperity Fund